✦ LIBER ✦

Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma

✍ Scribed by Peter Hersey; Malcolm Macdonald; Christopher Hall; Andrew Spurling; Anne Edwards; Alan Coates; William McCarthy

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 841 KB
Volume: 57
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19860415)57:8+<1666::aid-cncr2820571306>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical studies of recombinant interfer

Clinical studies of recombinant interferon alfa-2a (Roferon®-A) in cancer patients

✍ Tetsuo Taguchi 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

A Phase I study of interferon alfa-2a was conducted in 20 patients with disseminated cancer to establish the relationship between dose and interferon-related side effects. Fever was the most common side effect, and was not doserelated. Other side effects not related to dose included flu-like symptom

Clinical phase II trial of recombinant d

Clinical phase II trial of recombinant dna interferon (interferon alfa 2b) in patients with metastatic malignant melanoma

✍ Thierry Dorval; Thao Palangie; Michel Jouve; Emilio Garcia-Giralt; Lucien Israel 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 3 views

Safety and tolerance of recombinant inte

Safety and tolerance of recombinant interferon alfa-2a (roferon®-A) in Cancer Patients

✍ Gary J. Jones; Loretta M. Itri 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB

Retreatment of chronic hepatitis B e ant

Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa-2a

✍ Vicente Carreño; Patrick Marcellin; Stephanos Hadziyannis; Javier Salmerón; Mois 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

Recombinant interferon alfa-2a in advanc

Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic

✍ G. R. C. McLeod; D. B. Thomson; P. Hersey 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r

Three consecutive phase II studies of re

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

✍ Edward T. Creagan; David L. Ahmann; Stephen Frytak; Harry J. Long; M. N. Chang; 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 691 KB